Three consecutive related bone marrow transplants for juvenile myelomonocytic leukaemia.
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is the only cure for juvenile myelomonocytic leukaemia (JMML), but relapse remains the major cause of failure. A second transplant may be considered a way to induce the graft vs. leukaemia effect in patients who relapse after their first HSCT. We describe a 7-month-old girl with JMML who relapsed after a first, related allo-HSCT, and who again relapsed 8 months after the second transplant, despite discontinuation of immusuppressive therapy. She underwent a third allogeneic transplant from another related donor. At the time of this report the patient is in complete remission 26 months after the third transplant. We suggest that a third allo-HSCT may be taken into consideration for JMML patients who experience relapse, even after two previous transplants.
Faraci
Maura
M
Department of Pediatric Hematology/Oncology, G. Gaslini Children's Research Institute, Genova, Italy. maurafarci@ospendale-gaslini.ge.it
Micalizzi
Concetta
C
Lanino
Edoardo
E
Scuderi
Francesca
F
Morreale
Giuseppe
G
Dini
Giorgio
G
Cappelli
Barbara
B
Dallorso
Sandro
S
D016026:Bone Marrow Transplantation / Q000276:immunology / Q000502:physiology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D015479:Leukemia, Myelomonocytic, Acute / Q000628:therapy*; D019520:Living Donors; D012008:Recurrence; D018183:Transplantation Chimera; D016896:Treatment Outcome
D007166:Immunosuppressive Agents